Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

Red: Urano said as recently as February 17, 2015:

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30066
Posted On: 02/20/2015 2:04:37 PM
Posted By: Daveludlow
Red: Urano said as recently as February 17, 2015:

"MANF and its receptors are our targets. We are making progress."

He is not speaking about "recombinant MANF injections" here. Clearly you must understand that? Way back in June of 2014 recombinant MANF was his focus, but by September of 2014, he specifically said he preferred "small molecules" targeting "endogenous MANF" in the body. His September 2014 comment matches up with what he said again just last week on February 17th!!

Our patent only has to do with recombinant MANF!! The fact that you, Maui, Zoom, and others don't understand that....is perplexing! It is not helpful to be excited for things that are not true about MANF. There are articles talking about research on MANF that you guys talk about, which are not necessarily even referring to our recombinant MANF patent!!! But you guys don't seem to grasp that.

When Urano expressed his excitement over AMBS' gaining orphan status for MANF/Retinitis Pigmentosa, he was excited because he plans on using our recombinant MANF injections to treat eye damage in wolframs patients. But you interpreted his excitement incorrectly, thinking he was still using recombinant MANF to treat wolframs/diabetes itself. He hasn't talked of that since June 2014!!! Currently, he prefers targeting the endogenous MANF with small molecules. That you and the gang have made the term "small molecules" a point of ridicule has something to do with "group think" influences.

I just don't see how can you continue misunderstanding what Urano has been telling us?


(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us